Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

被引：77
作者：
Wang, Peipei [1 ]
Chen, Yueyun [1 ]
Wang, Chun [2 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Biotherapy, Canc Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
tumor neoantigen burden; biomarker; immunotherapy; immune response; tumor mutation burden; T-CELL THERAPY; LUNG-CANCER; IMMUNE; PREDICTION; INHIBITORS; LANDSCAPE; RESPONSES; IMPROVE;
D O I：
10.3389/fonc.2021.672677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy has significantly improved the clinical outcome of patients with cancer. However, the immune response rate varies greatly, possibly due to lack of effective biomarkers that can be used to distinguish responders from non-responders. Recently, clinical studies have associated high tumor neoantigen burden (TNB) with improved outcomes in patients treated with immunotherapy. Therefore, TNB has emerged as a biomarker for immunotherapy and other types of therapy. In the present review, the potential application of TNB as a biomarker was evaluated. The methods of neoantigen prediction were summarized and the mechanisms involved in TNB were investigated. The impact of high TNB and increased number of infiltrating immune cells on the efficacy of immunotherapy was also addressed. Finally, the future challenges of TNB were discussed.
引用
收藏
页数：8
相关论文
共 105 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
    Aversa, Ilenia
    Malanga, Donatella
    Fiume, Giuseppe
    Palmieri, Camillo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [3] Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy
    Bai, Peng
    Li, Yongzheng
    Zhou, Qiuping
    Xia, Jiaqi
    Wei, Peng-Cheng
    Deng, Hexiang
    Wu, Min
    Chan, Sanny K.
    Kappler, John W.
    Zhou, Yu
    Tran, Eric
    Marrack, Philippa
    Yin, Lei
    [J]. ONCOIMMUNOLOGY, 2021, 10 (01):
  • [4] Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
    Balachandran, Vinod P.
    Luksza, Marta
    Zhao, Julia N.
    Makarov, Vladimir
    Moral, John Alec
    Remark, Romain
    Herbst, Brian
    Askan, Gokce
    Bhanot, Umesh
    Senbabaoglu, Yasin
    Wells, Daniel K.
    Cary, Charles Ian Ormsby
    Grbovic-Huezo, Olivera
    Attiyeh, Marc
    Medina, Benjamin
    Zhang, Jennifer
    Loo, Jennifer
    Saglimbeni, Joseph
    Abu-Akeel, Mohsen
    Zappasodi, Roberta
    Riaz, Nadeem
    Smoragiewicz, Martin
    Kelley, Z. Larkin
    Basturk, Olca
    Goenen, Mithat
    Levine, Arnold J.
    Allen, Peter J.
    Fearon, Douglas T.
    Merad, Miriam
    Gnjatic, Sacha
    Iacobuzio-Donahue, Christine A.
    Wolchok, Jedd D.
    DeMatteo, Ronald P.
    Chan, Timothy A.
    Greenbaum, Benjamin D.
    Merghoub, Taha
    Leach, Steven D.
    [J]. NATURE, 2017, 551 (7681) : 512 - +
  • [5] The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution
    Ballhausen, Alexej
    Przybilla, Moritz Jakob
    Jendrusch, Michael
    Haupt, Saskia
    Pfaffendorf, Elisabeth
    Seidler, Florian
    Witt, Johannes
    Hernandez Sanchez, Alejandro
    Urban, Katharina
    Draxlbauer, Markus
    Krausert, Sonja
    Ahadova, Aysel
    Kalteis, Martin Simon
    Pfuderer, Pauline L.
    Heid, Daniel
    Stichel, Damian
    Gebert, Johannes
    Bonsack, Maria
    Schott, Sarah
    Blaeker, Hendrik
    Seppala, Toni
    Mecklin, Jukka-Pekka
    Ten Broeke, Sanne
    Nielsen, Maartje
    Heuveline, Vincent
    Krzykalla, Julia
    Benner, Axel
    Riemer, Angelika Beate
    von Knebel Doeberitz, Magnus
    Kloor, Matthias
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [6] DNA mismatch repair in cancer
    Baretti, Marina
    Le, Dung T.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2018, 189 : 45 - 62
  • [7] Personalized T cell-mediated cancer immunotherapy: progress and challenges
    Bethune, Michael T.
    Joglekar, Alok V.
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2017, 48 : 142 - 152
  • [8] Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
    Blaeschke, Franziska
    Paul, Milan Cedric
    Schuhmann, Martin Ulrich
    Rabsteyn, Armin
    Schroeder, Christopher
    Casadei, Nicolas
    Matthes, Jakob
    Mohr, Christopher
    Lotfi, Ramin
    Wagner, Beate
    Kaeuferle, Theresa
    Feucht, Judith
    Willier, Semjon
    Handgretinger, Rupert
    Stevanovic, Stefan
    Lang, Peter
    Feuchtinger, Tobias
    [J]. CYTOTHERAPY, 2019, 21 (09) : 973 - 986
  • [9] Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
    Blass, Eryn
    Ott, Patrick A.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (04) : 215 - 229
  • [10] Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
    Bulik-Sullivan, Brendan
    Busby, Jennifer
    Palmer, Christine D.
    Davis, Matthew J.
    Murphy, Tyler
    Clark, Andrew
    Busby, Michele
    Duke, Fujiko
    Yang, Aaron
    Young, Lauren
    Ojo, Noelle C.
    Caldwell, Kamilah
    Abhyankar, Jesse
    Boucher, Thomas
    Hart, Meghan G.
    Makarov, Vladimir
    De Montpreville, Vincent Thomas
    Mercier, Olaf
    Chan, Timothy A.
    Scagliotti, Giorgio
    Bironzo, Paolo
    Novello, Silvia
    Karachaliou, Niki
    Rosell, Rafael
    Anderson, Ian
    Gabrail, Nashat
    Hrom, John
    Limvarapuss, Chainarong
    Choquette, Karin
    Spira, Alexander
    Rousseau, Raphael
    Voong, Cynthia
    Rizvi, Naiyer A.
    Fadel, Elie
    Frattini, Mark
    Jooss, Karin
    Skoberne, Mojca
    Francis, Joshua
    Yelensky, Roman
    [J]. NATURE BIOTECHNOLOGY, 2019, 37 (01) : 55 - +
12345678910